ABOUT US ALLERGIES PATIENTS SCIENCE NEWS CENTER CAREERS Find your location Science Our approach to AIT Our approach to allergen immunotherapy Our approach to AIT Clinical Development Manufacturing SCIENCE OUR APPROACH TO ALLERGEN IMMUNOTHERAPY Stallergenes Greer is committed to promoting progress in allergen immunotherapy treatments A consistent development path From diagnosis to treatment, Stallergenes Greer’s portfolio is designed to ensure the consistency of our products, in terms of: reactivity index source of raw materials high quality standards Stallergenes Greer’s marketed products are tested through clinical trials to evaluate the short- and long-term efficacy and tolerability of treatments. In the US, our allergens are FDA approved. Our therapeutic approach Allergen immunotherapy (AIT) is the only therapeutic class capable of modifying disease progression and potentially preventing the onset of the disease. AIT consists in administering allergens by sublingual or subcutaneous route, thus allowing the reorientation of the immune responses of patients towards allergen-specific tolerance induction. Precision medicine for better patient care Stallergenes Greer is committed to furthering precision medicine and personalised AIT treatments to address unmet medical needs for patients with allergies. With precision medicine, Stallergenes Greer identifies the mechanisms of allergic response to develop best in class diagnostic tools and personalised allergen immunotherapy treatments. We are committed to delivering unparalleled patient care through our extensive product portfolio which covers all administration (subcutaneous and sublingual) routes and personalised treatment solutions which meet the needs of both individual patient-profiles and the medical community. A high level of scientific expertise Each allergen source contains several molecules which are recognised by the immune system as allergens and will trigger an allergic reaction. Allergens are large, complex molecules composed of a multitude of atoms. Working with large molecules requires a high level of scientific expertise and state-of-the-art technologies to characterise and quantify allergens. Specific processes are required due to both the complexity of the molecules and their biological nature. A focused approach to innovation At Stallergenes Greer, we have been working with allergens for more than 100 years. We aim to develop treatments that address the unmet needs of a growing number of allergy patients around the world. We focus our efforts on allergen characterisation as well as on optimal approaches to deliver allergens to the immune system. Our long-standing work on the mechanisms of action of AIT has enabled us to identify candidate biomarkers which correlate with clinical outcomes observed in double-blind placebo-controlled AIT trials. These candidates could be used either as predictive or follow-up biomarkers in line with our commitment to explore further allergy diagnosis and treatment personalisation. Pharmaceutical dévelopment Research and development includes the pharmaceutical development of formulations from initial stages (active pharmaceutical ingredient characterisation, screening) to industrialisation. Find out more about Stallergenes Greer’s lab-scale pharmaceutical development : © 2021 Stallergenes Greer Site Map Terms & Conditions Modern Slavery Act Statement Contact Cookie Policy Personal Data Protection Policy Cookies Reject and continue STALLERGENES GREER uses technical cookies essential for the functioning of the site as well as audience measurement cookies. You can accept audience measurement cookies by clicking on “Accept” or reject them by clicking on “Reject and continue”. You can change your mind at any time by clicking on “Cookies Management” and manage your preferences by clicking on “Set your preferences”. For more information, please read our Cookie Policy Set your preferences Accept